

**Press Release**

Monday, December 21, 2015

Strides Shasun Limited

(formerly Strides Arcolab Limited)

Strides House, Bannerghatta Road,

Bangalore – 560076.

Strides Shasun receives approval from Drug Controller General of India for generic version of Sofosbuvir

Bangalore, December 21, 2015. Strides Shasun Limited today announced that it has received approval for manufacturing generic version of **Sofosbuvir 400 mg** (Gilead's Sovaldi) from Drug Controller General of India, Government of India.

In September 2014, Strides entered into a licensing agreement with Gilead Sciences, Inc to bring Hepatitis C cure to 91 developing countries. The product will continue to be marketed under the brand name '**Virso**' in India and overseas.

Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for Hepatitis C treatment and represents a paradigm shift in the existing Hepatitis C cure. The high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions of Sofosbuvir makes it a breakthrough drug in Hepatitis C treatment. This drug in combination therapy has shown to have high cure rates of around 90%.

Globally, it is estimated that 170-185 million people (about 3% of the world's population) are chronically infected with Hepatitis C virus (HCV). In India alone, it is estimated that 12-18 million patients are infected with Hepatitis C, which is several fold greater than those with HIV/AIDS.

About Strides Shasun Limited

Strides Shasun, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.

The Company has global manufacturing foot print with 12 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 6 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

<p><u>Strides Shasun</u></p> <p>Mohan Kumar, CEO - Pharma +91 80 6784 0748</p> <p>Vikesh Kumar +91 80 6784 0827 Kannan N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791</p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com</p> <p>K Priya: +91 9535425418 priya@fortunapr.com</p>
---	--